clinical trial · NCT03776071
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
GlioblastomaEnzastaurin HydrochloridePlaceboTemozolomideRadiotherapy
brief summary
This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
started
Dec 16, 2020
primary completion
Feb 29, 2024
completion
Feb 29, 2024
last updated
Apr 22, 2024
official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol